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Abstract
Background
Schistosomiasis affects over 200 million people and there are concerns whether the current
chemotherapeutic control strategy (periodic mass drug administration with praziquantel
(PZQ)—the only licenced anti-schistosome compound) is sustainable, necessitating the
development of new drugs.
Methodology/Principal findings
We investigated the anti-schistosome efficacy of polypyridylruthenium(II) complexes and
showed they were active against all intra-mammalian stages of S. mansoni. Two com-
pounds, Rubb12-tri and Rubb7-tnl, which were among the most potent in their ability to kill
schistosomula and adult worms and inhibit egg hatching in vitro, were assessed for their effi-
cacy in a mouse model of schistosomiasis using 5 consecutive daily i.v. doses of 2 mg/kg
(Rubb12-tri) and 10 mg/kg (Rubb7-tnl). Mice treated with Rubb12-tri showed an average 42%
reduction (P = 0.009), over two independent trials, in adult worm burden. Liver egg burdens
were not significantly decreased in either drug-treated group but ova from both of these
groups showed significant decreases in hatching ability (Rubb12-tri—68%, Rubb7-tnl—56%)
and were significantly morphologically altered (Rubb12-tri—62% abnormal, Rubb7-tnl—35%
abnormal). We hypothesize that the drugs exerted their activity, at least partially, through
inhibition of both neuronal and tegumental acetylcholinesterases (AChEs), as worms
treated in vitro showed significant decreases in activity of these enzymes. Further, treated
parasites exhibited a significantly decreased ability to uptake glucose, significantly depleted
glycogen stores and withered tubercules (a site of glycogen storage), implying drug-medi-
ated interference in this nutrient acquisition pathway.
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Conclusions/Significance
Our data provide compelling evidence that ruthenium complexes are effective against all
intra-mammalian stages of schistosomes, including schistosomula (refractory to PZQ) and
eggs (agents of disease transmissibility). Further, the results of this study suggest that
schistosome AChE is a target of ruthenium drugs, a finding that can inform modification of
current compounds to identify analogues which are even more effective and selective
against schistosomes.
Author summary
Schistosomiasis is a neglected tropical disease which affects over 200 million people and
there is only one licensed drug, praziquantel, currently available for treatment. In a search
for new drugs to control schistosomiasis, we tested the anti-schistosome efficacy of a series
of ruthenium compounds and found that a number of them were able to inhibit parasite
eggs from hatching and kill adult worms and praziquantel-refractory juvenile worms in
vitro. We demonstrated that the compounds inhibit schistosome acetylcholinesterase (the
enzyme that breaks down the neurotransmitter acetylcholine), which could potentially
result in paralysis of the parasite, likely due to uncontrolled neuromuscular function
caused by acetylcholine excess. Moreover, we showed that drug-treated worms had a sig-
nificantly reduced ability to uptake exogenous glucose and markedly depleted glycogen
stores, presumably through inhibition of the acetylcholinesterase-mediated glucose scav-
enging pathway. Lastly, we found that two of the drugs—Rubb12-tri and Rubb7-tnl—when
used to treat schistosome-infected mice, were able to reduce worm burdens and signifi-
cantly affect the viability of parasite eggs in vivo, which would have a marked impact on
disease transmission. We believe that these complexes are desirable drug lead scaffolds
which could be used to develop effective and selective compounds to control and treat
schistosomiasis and, potentially, other parasitic diseases.
Introduction
More than half a billion people are at risk of contracting schistosomiasis (bilharzia), a
neglected tropical parasitic disease that is endemic in more than 75 countries in Africa, Asia,
and South America, where over 200 million individuals are infected and approximately
280,000 die every year [1, 2]. Schistosomiasis is caused by infection with blood flukes of the
genus Schistosoma, and disease results from the deposition of eggs in host tissues, leading to
granuloma formation that can cause fibrosis, portal hypertension, and even death [3].
Despite this considerable disease burden, to date there are no vaccines against schistosomi-
asis [4]. Praziquantel (PZQ) remains the only effective frontline drug to treat the parasite
despite its shortcomings, which include ineffectiveness against juvenile stages of the worm [5],
poor efficacy in treating pre-patent infections [6], reports of reduced efficacy in field studies
[7] and the inevitable risk of the development of resistant strains in response to periodic mass
drug administration [8]. Since there are no alternative effective drug treatments for these para-
sites, new therapies are urgently required.
Among potential targets for chemotherapy are acetylcholinesterases (AChEs). These
enzymes catalyze the rapid breakdown of the neurotransmitter acetylcholine (ACh) in both
Ruthenium complexes as anti-schistosome drugs
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006134 December 14, 2017 2 / 21
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
central and peripheral nervous systems of eukaryotic organisms, and so control neuronal func-
tion [9]. In addition to controlling cholinergic synapses, the enzyme is present in large
amounts on the tegument of schistosomes [10], where it has been implicated to play a role in
the regulation of host glucose uptake by the parasite by limiting the interaction of host ACh
with tegumental nicotinic ACh receptors (nAChRs) [11]. These receptors are associated both
spatially and temporally with surface AChE expression and are concentrated on the tegument
[12], the major site of glucose uptake [13]. Evidence for this relationship is shown by the abla-
tion of glucose uptake with a membrane-impermeable inhibitor of AChE (which has the same
result as the administration of an excess of ACh) or specific agonists of nAChRs. The interac-
tion of ACh with tegumental nAChRs is thought to decrease the amount of glucose uptake
through surface glucose transporters but the specific mechanism for this is not known [11].
With respect to its termination of synaptic transmission, inhibition of AChE produces an
excess accumulation of ACh and overstimulation of its receptors, causing uncoordinated neu-
romuscular function that often results in death due to respiratory paralysis [14]. As such,
AChE inhibitors are widely used as pesticides [15] and anthelmintics [16]. Indeed, metrifo-
nate, an organophosphorus AChE inhibitor originally used as an insecticide has also been
used for the treatment of schistosomiasis until it was withdrawn from the market and further
development because of off-target toxicity [17].
In addition to organophosphates, mono-nucleated chemical complexes of the transition
metal ruthenium have been shown to target and inhibit enzymes such as AChE [18], and there
are numerous recent studies documenting the efficacy of polypyridylruthenium(II) complexes
against a variety of different microbial pathogens [19–21]. Unlike their organophosphorus
counterparts, ruthenium complexes are speculated to exert their inhibitory effects through a
combination of electrostatic and hydrophobic interactions at the peripheral anionic (PAS) site
of AChE, which is located at the gate of the enzyme’s catalytic gorge [22], and not through
direct interaction with the active site. Ruthenium complexes are thought to be less toxic to
human cells than small-molecule inhibitors because of this mode of inhibition and also
because the overall neutral charge in the outer membrane leaflet of eukaryotic cells [23] creates
a greatly reduced capacity for electrostatic interaction with the metal compounds [24].
Herein, we demonstrate the AChE-inhibitory action of two mononuclear and a series of
di-, tri- and tetra-nuclear polypyridylruthenium(II) complexes linked by the bis[4(4’-methyl-
2,2’-bipyridyl)]-1,n-alkane ligand (“bbn”; n = 7, 10, 12 and 16) against extracts of Schistosoma
mansoni and Schistosoma haematobium and both adult and juvenile S. mansoni parasites in
vitro. We also provide evidence consistent with the capacity of these complexes to disrupt the
parasite’s glucose uptake ability through the inhibition of tegumental AChE, a cholinergic
pathway unique to schistosomes [11]. Finally, we show the in vivo efficacy of two ruthenium
complexes in a mouse model of schistosomiasis, providing evidence that drugs based on
these compounds could be a valuable addition to the chemotherapeutic arsenal against this
debilitating disease.
Methods
Nomenclature and preparation of ruthenium complexes
[Ru(phen)2(Me2bpy)]
2+ and the mononuclear (Rubbn-mono), dinuclear (Rubbn-di), trinuc-
lear (Rubbn-tri), tetranuclear linear (Rubbn-tl) and tetranuclear non-linear (Rubbn-tnl) poly-
pyridylruthenium(II) complexes (Fig 1) were synthesised using the appropriate bis[40-(4-
methyl-2,20-bipyridyl)]-1,n-alkane bridging ligand (bbn) as previously described [19]. Com-
pounds were dissolved in H2O at stock concentrations of 1 mM.
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Parasites and extracts
S. mansoni cercariae were shed from infected Biomphalaria glabrata snails (Biomedical
Research Facility, MD, USA) by exposure to light at 28˚C for 2 hours. Cercariae were used to
infect 6–8 week old male BALB/c mice (Animal Resources Centre, WA, Australia) by tail pene-
tration (180 S. mansoni cercariae/mouse) and adults were harvested by vascular perfusion at 7
weeks post-infection [25]. S. mansoni eggs were purified from infected mouse livers as previ-
ously described [26] and were used in the xWORM egg hatching assay or to make soluble egg
antigen (SEA) [27]. For experiments involving schistosomula, S. mansoni cercariae were
mechanically transformed as previously described [27]. To make PBS-soluble extracts, S. man-
soni adult worms were homogenized in PBS (50 μl/worm pair) at 4˚C using a TissueLyser II
(Qiagen) and the supernatant collected by centrifugation at 15,000 g for 60 mins at 4˚C. Triton
X-100-soluble extracts of S. mansoni and S. haematobium were made in the same way except
worms were lysed in buffer containing 1% Triton X-100, 40 mM Tris-HCl, pH 7.4. Protein
concentration was determined using the Pierce BCA Protein Assay kit (Thermofisher), ali-
quoted and stored at -80˚C until use.
Enzyme activity in parasite extracts and inhibition assays
AChE, nucleotide pyrophosphatase-phosphodiesterase 5 (SmNPP-5) and alkaline phosphatase
(AP) activity in Triton X-100-soluble adult worm extracts and AChE activity in SEA were
determined in a Polarstar Omega microplate reader (200 μl final volume in 96-well plates).
AChE activity was determined using the Ellman method [28]; extracts were serially diluted
(20–5 μg) in AChE assay buffer (0.1 M sodium phosphate, pH 7.4), 2 mM acetylthiocholine
(AcSCh) and 0.5 mM 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) were added and absorbance
Fig 1. The kinetically inert tri-nuclear (Rubbn-tri), linear tetra-nuclear Rubbn-tl and non-linear tetra-nuclear Rubbn-tnl) ruthenium(II)
complexes.
https://doi.org/10.1371/journal.pntd.0006134.g001
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was measured at 405 nm every 10 min for 5 h at 37˚C. Specific activity was calculated using the
initial velocity of the reaction. For AChE inhibition assays, parasite extracts equal to a specific
activity of 0.55 nmol/min/well were diluted in AChE assay buffer to a final volume of 170 μl
and pre-incubated with ruthenium complexes (10 nM– 100 μM) for 20 min at RT. AcSCh and
DTNB were added at 2 mM and 0.5 mM, respectively and absorbance was measured at 405
nm every 10 min for 5 h at 37˚C. SmNPP-5 activity [29] was measured by serially diluting
extracts in SmNPP-5 assay buffer (50 mM Tris-HCl, pH 8.9, 120 mM NaCl, 5 mM KCl, 60
mM glucose), adding 0.5 mM p-nitrophenyl thymidine 50-monophosphate (p-Nph-5’-TMP)
and reading the absorbance (405 nm) every 10 min for 5 h at 37˚C. Specific activity was calcu-
lated using the initial velocity of the reaction. For SmNPP-5 inhibition assays, parasite extract
equal to 32 nmol/min/well was diluted in SmNPP-5 assay buffer to a final volume of 180 μl
and pre-incubated with ruthenium complexes (10 nM– 100 μM) for 20 min at RT. Substrate
(p-Nph-5’-TMP) was added to 0.5 mM and absorbance was measured at 405 nm every 10 min
for 5 h at 37˚C. AP activity [30] was measured by serially diluting extracts in AP assay buffer
(0.1 M glycine, pH 10.4, 1 mM MgCl2, 1 mM ZnCl2), adding 2 mM p-nitrophenyl phosphate
(pNPP) and measuring absorbance (λ = 405 nm) every 2 min for 1 h at 37˚C. Specific activity
was calculated using the initial velocity of the reaction. For AP inhibition assays, parasite
extract equal to 1 nmol/min/well was diluted in AP assay buffer to a final volume of 180 μl and
pre-incubated with ruthenium complexes (10 nM– 100 μM) for 20 min at RT. Substrate
(pNPP) was added to 2 mM and absorbance was measured at 405 nm every 2 min for 1 h at
37˚C. For all assays, inhibition for each sample was calculated relative to the negative control
(reactions without ruthenium complexes) and reactions were performed in duplicate with data
presented as the average ± SEM.
Effect of ruthenium complexes against larval S. mansoni parasites
Newly-transformed schistosomula (100 parasites) were cultured (37˚C, 5% CO2) in 200 μl of
Basch medium supplemented with 4× antibiotic/antimycotic (AA—200 units/ml penicillin,
200 μg/ml streptomycin and 0.5 μg/ml amphotericin B) in a 96 well plate in the presence of a
series of serially-diluted ruthenium complexes (100 μM– 10 nM). After 48 h, parasite viability
was assessed microscopically by trypan blue exclusion staining as previously described [31].
Six of the most effective compounds were tested again for their larvacidal efficacy (100 schisto-
somula per treatment); this time at concentrations of 200, 100, 50, 25, 12.5 and 6.25 μM. Exper-
iments were performed in duplicate with IC50 data presented as the average ± SE.
Effect of ruthenium complexes against adult S. mansoni parasites
Five pairs of adult worms were cultured in 2 ml of Basch medium supplemented with 4x AA in
a 24 well plate in the presence of ruthenium complexes (50 μM). Control worms were treated
with an equal amount of H2O. Worms were cultured at 37˚C and 5% CO2 for 7 days, moni-
tored every 24 h for motility by microscopic examination and considered dead if no movement
was seen. The most effective ruthenium complexes (5 compounds) were tested in duplicate
(five pairs of worms each) at 10, 50 and 100 μM. Data is presented as the average of each dupli-
cate experiment ± SE.
Effect of ruthenium complexes on S. mansoni egg hatching and
development
Egg hatching was evaluated by the xWORM egg hatching assay [32]. Ova (5,000 per well,
200 μl reaction volume) were incubated in 0.1x PBS, pH 7.2, containing ruthenium com-
plexes (50 μM) and induced to hatch under bright light at RT for 16 h. The motility of the
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miracidia released from the hatched eggs was monitored every 15 s and the motility index
was calculated as described [32]. Experiments were performed in triplicate with control reac-
tions containing no ruthenium compounds. To investigate the effects of ruthenium com-
plexes on egg development, triplicate sets of five pairs of adult S. mansoni worms were
cultured in Basch media with or without 5 μM Rubb12-tri, for 72 h. The eggs released into the
media were counted and misshapen, malformed or immature eggs [33] were scored as
“abnormally developed”. Egg hatching and morphology data are presented as the average of
each triplicate experiment ± SE.
Assessment of enzyme inhibitory effects induced by treatment of worms
with ruthenium complexes
Freshly perfused worms were cultured in the presence of sub-lethal concentrations (5 μM) of
Rubb12-tri or Rubb16-tnl—two ruthenium compounds determined to be most effective in
terms of their combined activity against schistosomula, adult worms and eggs—in Basch
medium at 37˚C and 5% CO2. To measure surface AChE or AP activity, 5 pairs of worms (pre-
liminary experiments by us showed this number of parasites was sufficient to accurately mea-
sure surface enzyme activity) were transferred to either AChE assay buffer (0.1 M sodium
phosphate, pH 7.4, 2 mM AcSCh, 0.5 mM DTNB) or AP assay buffer (0.1 M glycine, pH 10.4,
1 mM MgCl2, 1 mM ZnCl2, 2mM p-nitrophenyl phosphate). Surface enzyme activities were
quantified by measuring the absorbance (λ = 405 nm) after incubation for 60 min (AChE) or
30 min (AP). Activity was measured from triplicate sets of parasites (5 pairs of worms) and
each assay was technically replicated three times. For each enzyme assay, activities of drug-
treated parasites were expressed relative to worms cultured without ruthenium complexes
(negative controls). To measure somatic AChE activity, PBS-soluble extracts were made from
worms used for surface AChE activity (triplicate sets of five pairs of worms) and then assayed
in triplicate as described above. Data is presented as the average of each triplicate biological
and technical experiment ± SE.
Effect of glucose uptake and glycogen storage on worms treated with
ruthenium complexes
Five pairs of freshly-perfused worms were cultured in the presence of sub-lethal concentra-
tions (5 μM) of Rubb12-tri or Rubb16-tnl in DMEM (1000 mg/l glucose). Media (20 μl) from
each experiment was collected after 24 h and the amount of glucose was quantified using a col-
orimetric glucose assay kit (Sigma) according to the manufacturer’s instructions. Media was
collected from triplicate sets of parasites (five pairs of worms) and each assay was replicated 3
times. Glucose levels were expressed relative to media collected from worms which received
no drug (negative control). Data is presented as the average of each triplicate biological and
technical experiment ± SE. To measure the glycogen content of worms treated with ruthenium
drugs, Triton X-100-soluble extracts were made and assayed for glycogen in a modified proce-
dure described by Gomez- Lechon et al. [34]. Briefly, 0.2 M sodium acetate, pH 4.8, was added
to 30 μg parasite extract and 50 μl glucoamylase (10 U/ml) to make a reaction volume of
150 μl. The mixture was incubated at 40˚C for 2 h with shaking at 100 rpm, 40 μl added to a
new microplate with 10 μl 0.25 M NaOH and the amount of glucose quantified using the color-
imetric glucose assay kit. Extracts were made from triplicate sets of parasites (five pairs of
worms) and assays were performed three times. Data is presented as the average of each tripli-
cate biological and technical experiment ± SE.
Ruthenium complexes as anti-schistosome drugs
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Scanning electron microscopy
Control parasites and worms treated with 5 μM Rubb12-tri were prepared for scanning elec-
tron microscopy by fixation in 3% glutaraldehyde followed by successive dehydration for 15
mins each in a graded ethanol series (100%, 90%, 80%, 70%, 60%, 50%), 1:1 ethanol:hexam-
ethyldisilizane (HMDS) and, finally, 100% HMDS. Dehydrated worms were covered and left
overnight in a fume hood to allow the HMDS to evaporate then mounted on an aluminium
stub, sputtered with gold and visualized using a JEOL JSM scanning electron microscope oper-
ating at 10 kV. Images were acquired digitally using Semaphore software.
Cytotoxicity assays
Cytotoxicity assays were performed using the mitochondrial-dependent reduction of 3-
(3,4-dimethylthiazol-2yl)-5-diphenyl tetrazolium bromide (MTT) to formazan as described by
Pandrala et al. [35]. The human bile duct cell line H69 was cultured in 96-well microtiter plates
containing 0.1 ml of growth factor-supplemented media (DMEM/F12 with high glucose (4
mg/ml), 10% FCS, 1×AA, 25 μg/ml adenine, 5 μg/ml insulin, 1 μg/ml epinephrine, 8.3 μg/ml
holo-transferrin, 0.62 μg/ml hydrocortisone, 13.6 ng/ml triiodo-1-thyronine (T3) and 10 ng/
ml epithelial growth factor (EGF)) [36] to a cell density of 5,000 per well at 37˚C in 5% CO2.
Cell viability was assessed after continuous exposure to a concentration series (50, 25, 10, 5, 1,
0.5 and 0.1 μM) of Rubb12-tri, Rubb16-tnl, PZQ or dichlorvos—a metabolite of the anti-schis-
tosome AChE inhibitor metrifonate—for 72 h. The amount of reduced MTT to formazan
within the cells was quantified by measuring the absorbance at λ = 550 nm. Data are the aver-
age of six replicate experiments ± SE.
Tolerability study
In order to determine the maximum tolerated dose of Rubb12-tri and Rubb7-tnl to be adminis-
tered to mice infected with S. mansoni, five intravenous (i.v.) doses (tail vein) of Rubb12-tri
and Rubb7-tnl were given to groups of three male BALB/c mice (6–8 weeks) daily for five con-
secutive days. The doses ranged from 0.25 to 10 mg/kg in PBS and were administered in a vol-
ume of 30 μl. Animals were closely monitored for adverse clinical signs throughout the study
and mice showing adverse effects were euthanized using CO2 asphyxiation. The highest dose
that did not cause any adverse clinical signs was considered to be the maximum tolerated dose
(MTD) for five consecutive daily doses.
In vivo efficacy of ruthenium complexes
Groups of 8 male BALB/c mice (6–8 weeks) were infected with S. mansoni cercariae as
described above. At 35 days post-infection, groups were given five consecutive daily i.v. doses
(tail vein—30 μl) of the MTD of either Rubb12-tri (2 mg/kg in PBS) or Rubb7-tnl (10 mg/kg in
PBS). PBS was similarly administered to the control group. Two independent trials were per-
formed. Parasites were harvested by vascular perfusion at 49 days post-infection and the aver-
age worm burden per mouse for each group of mice (trial 1 PBS control—n = 8 mice, trial 1
Rubb12-tri-treated—n = 8 mice, trial 1 Rubb7-tnl-treated—n = 6 mice, trial 2 PBS control—
n = 7 mice, trial 2 Rubb12-tri-treated—n = 7 mice, trial 2 Rubb7-tnl-treated—n = 8 mice) was
calculated. Data is presented as a combination of the two independent trials ± SE. Livers from
each group (trial 1 PBS control—n = 8 mice, trial 1 Rubb12-tri-treated—n = 8 mice, trial 1
Rubb7-tnl-treated—n = 6 mice, trial 2 PBS control—n = 7 mice, trial 2 Rubb12-tri-treated—
n = 7 mice, trial 2 Rubb7-tnl-treated—n = 8 mice) were collected, halved and weighed, with
one half digested with 5% KOH to determine liver eggs per gram of tissue (epg) as previously
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described [37]. The other half of each liver was pooled according to group, homogenized in
H2O and placed in identical foil-covered volumetric flasks under bright light to hatch eggs
released from the livers. After 1 h, the number of miracidia in 10 x 50 μl aliquots of H2O (sam-
pled from the extreme top of each flask) were counted. The amount of eggs in each flask at the
start of the hatching experiment was determined by liver epg calculations, allowing the egg
hatching index of each group to be calculated by expressing the hatched eggs (miracidia) as a
percentage of the total eggs. Data presented is for trial 1 only and represents the average of ten
counts ± SE. To assess fitness of parasites recovered from mice treated with ruthenium com-
plexes compared to controls, worms recovered from each group were pooled and five pairs
were assayed for surface enzyme activity (Sm-AChE, SmNPP-5 and Sm-AP) or glucose uptake
ability as described above. Somatic Sm-AChE activity was determined from homogenates
made from the worms assayed for surface Sm-AChE activity, also as described above. Each
assay was technically replicated three times and data is presented as the average of triplicate
technical replicates of both trials combined ± SE. To compare eggs released from parasites
recovered from mice treated with ruthenium complexes and controls, triplicate sets of worms
(five pairs) from each pool were incubated in Basch media at 37˚C in 5% CO2 for 72 h. The
number of eggs released were counted and scored on the basis of development and morphol-
ogy [33] by visualization under a FITC filter on a Zeiss AxioImager-M1 fluorescent micro-
scope. Data presented is for trial 2 and is the average of triplicate experiments ± SE.
Statistical analyses
Statistical analyses were performed using Graphpad Prism 7. Inhibition curves and IC50 values
were generated using sigmoidal dose-response (variable slope) with a non-linear fit model.
One-way ANOVA with Dunn’s multiple comparison was used to determine significance (p),
which was set at 0.05. In the case where only two groups were compared, student’s t test was
used.
Animal ethics approval
The James Cook University (JCU) animal ethics committee approved all experimental work
involving animals (ethics approval number A2271). Mice were raised in cages in the JCU quar-
antine facility for the duration of the experiments in compliance with the 2007 Australian
Code of Practice for the Care and use of Animals for Scientific Purposes and the 2001 Queens-
land Animal Care and Protection Act. All reasonable efforts were made to minimise animal
suffering.
Results
Inhibition of AChE in schistosome extracts by ruthenium complexes
A series of ruthenium complexes of different nuclearity (mono-, di-, tri- and tetra-linear and
tetra-nonlinear) and with different chain lengths in the linking ligand (bb7, bb10, bb12, bb16)
were screened (1 μM) for AChE inhibitory activity in Triton X-100-soluble extracts from adult
S. mansoni and S. haematobium and S. mansoni soluble egg antigen (SEA) (Table 1). In S. man-
soni extracts, all tri- and tetra-nuclear complexes inhibited AChE activity by 70–90% and 7 of
the 13 compounds had IC50 values 1 μM. A dose-response curve and Lineweaver-Burk plot
is shown for the most potent of these complexes (Rubb12-tri, IC50 = 0.3 μM) (Fig 2).
Interestingly, a different pattern of inhibition by the ruthenium complexes was observed
against AChE activity in S. haematobium extracts with the IC50 values being considerably
more varied than was observed for AChE activity in S. mansoni adult extracts, and not all
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compounds showed correlated potency between the two species. In addition, there was more
variability among the tri- and tetra-nuclear complexes with the more lipophilic complexes
(e.g. Rubb10-tri and Rubb12-tri) having stronger inhibitory activity. Rubb12-mono, Rubb12-tri
and Rubb12-tnl showed greater activity and the IC50 values of these complexes were less than
1 μM. Overall, ruthenium compounds displayed a similar pattern of inhibition against AChE
activity in S. mansoni egg versus adult extracts, although most complexes showed a stronger
Table 1. Inhibition of acetylcholinesterase (AChE) activity in adult S. mansoni and S. haematobium Triton X-100-soluble extracts and S. mansoni
soluble egg extract (SEA) by a series of ruthenium complexes.
ta S. mansoni extract S. haematobium extract S. mansoni SEA
AChE Inhibition (%)a, b IC50 (μM)b AChE Inhibition (%)a, b IC50 (μM)b AChE Inhibition (%)a, b IC50 (μM)b
Ru(phen)2(Me2bpy) 9.3 ± 1.8 67.0 ± 11.6 13.3 ± 1.8 90.2 ± 1.2 66.5 ± 5.8 ND
Rubb12-mono 11.1 ± 0.8 18.9 ± 2.8 52.2 ± 0.5 1.1 ± 0.1 73.5 ± 4.9 ND
Rubb12-di 73.9 ± 0.5 1.6 ± 0.3 20.9 ± 0.2 16.8 ± 0.4 94.2 ± 0.8 ND
Rubb7-tri 84.3 ± 4.5 0.4 ± 0.0 37.2 ± 0.3 0.4 ± 0.0 77.5 ± 0.6 ND
Rubb10-tri 78.7 ± 0.7 0.5 ± 0.0 73.6 ± 2.0 3.0 ± 0.0 91.3 ± 0.3 ND
Rubb12-tri 89.4 ± 0.4 0.3 ± 0.0 87.6 ± 0.4 0.7 ± 0.0 96.3 ± 1.4 0.2 ± 0.0
Rubb16-tri 46.8 ± 1.1 1.9 ± 0.0 31.6 ± 0.5 18.0 ± 0.1 89.7 ± 0.1 ND
Rubb7-tl 73.4 ± 1.5 1.0 ± 0.0 24.8 ± 0.3 36.4 ± 4.4 78.7 ± 8.0 ND
Rubb12-tl 89.9 ± 1.6 0.3 ± 0.0 55.4 ± 2.6 1.0 ± 0.1 97.2 ± 0.6 0.2 ± 0.0
Rubb16-tl 76.3 ± 1.6 2.4 ± 0.1 59.3 ± 0.1 1.9 ± 0.1 90.8 ± 0.2 ND
Rubb7-tnl 84.0 ± 0.6 0.9 ± 0.1 19.5 ± 0.3 ND 98.1 ± 0.3 ND
Rubb12-tnl 80.0 ± 0.1 0.4 ± 0.0 75.9 ± 2.5 3.2 ± 0.0 92.7 ± 0.3 0.3 ± 0.0
Rubb16-tnl 73.0 ± 0.8 2.3 ± 0.1 51.1 ± 6.0 ND 89.6 ± 0.1 ND
ainhibition of Sm-AChE activity assessed at 1μM.
bdata represents the mean of duplicate experiments ± SE
https://doi.org/10.1371/journal.pntd.0006134.t001
Fig 2. Effect of ruthenium complexes on AChE activity in adult S. mansoni extracts. Concentration-dependent inhibition of AChE activity
in S. mansoni adult extracts when treated with Rubb12-tri, a representative member of the ruthenium complexes tested, as determined by
Ellman assay. (A) Dose-response curve of Rubb12-tri. (B) Lineweaver-Burk inhibition plot of AChE activity in S. mansoni adult extracts in the
presence of Rubb12-tri. Data represent the average of triplicate experiments ± SE.
https://doi.org/10.1371/journal.pntd.0006134.g002
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inhibitory capacity towards AChE activity in SEA with three compounds (Rubb12-tri, Rubb12-
tl and Rubb7-tnl) achieving >95% inhibition.
In order to examine the selectivity for AChE, the series of ruthenium complexes was
screened (10 μM) against S. mansoni extract for inhibition of two major tegumental enzymes
—the phosphodiesterase SmNPP-5 and alkaline phosphatase (AP). None of the compounds
strongly inhibited activity of either enzyme at 10 μM, a tenfold higher concentration than was
used for the AChE inhibition assays (S1 Table).
In vitro effect of ruthenium complexes on larval S. mansoni parasites
The entire series of Ru complexes were screened for their larvacidal activity against S. mansoni
schistosomula with IC50 values calculated for the most effective compounds in a separate
experiment. (Table 2).
In vitro effect of ruthenium complexes on adult S. mansoni parasites
S. mansoni worms were cultured in the presence of 50 μM of each ruthenium complex to
investigate their effectiveness in killing adult parasites, which was assessed by lack of motility.
The effects of selected compounds on worm survival is shown in Fig 3A. Similar to the enzyme
inhibition in parasite extracts, the tri-and tetra-nuclear complexes were the most effective
compared to the mono- and di-nuclear complexes. The killing ability increased with the
increasing number of ruthenium centres in the complex, and the tetra-nonlinear complexes
were more active in comparison with their linear counterparts. As with the schistosomula kill-
ing experiment, the most effective compounds (five) were tested again, this time at concentra-
tions of 100 μM, 50 μM and 10 μM (Fig 3B). All tri-and tetra-nuclear complexes (10 μM) killed
100% of the parasites in six days. Treatment with the ruthenium complexes induced significant
changes in the gross morphology of the parasites (Fig 3C). In particular, a tight coiling of the
treated worms was observed.
In vitro effect of ruthenium complexes on S. mansoni egg hatching and
development
S. mansoni egg hatching in the presence (50 μM) of ruthenium complexes was investigated by
measuring the motility index of hatched miracidia from eggs using the xWORM assay (Fig
4A). Significant reduction in hatching/motility was observed for 9/13 compounds tested.
Rubb12-tnl was the most effective, reducing the motility index by 67% (P< 0.0001). To analyze
the effect of ruthenium complexes on egg development, the eggs released from worms incu-
bated for 3 days in the presence of 5 μM Rubb12-tri were scored for morphology. Eggs released
Table 2. Potency of selected ruthenium complexes against S. mansoni schistosomula after 48 h
treatment.
Compound IC50 (μM)1
Rubb12-tri 45.1 ± 4.8
Rubb12-tl 68.5 ± 3.6
Rubb12-tnl 42.8 ± 1.2
Rubb7-tl 81.3 ± 0.6
Rubb7-tnl 30.3 ± 2.0
Rubb16-tnl 27.3 ± 0.4
1data represents the mean of duplicate experiments ± SE
https://doi.org/10.1371/journal.pntd.0006134.t002
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from treated worms were abnormally developed (immature or misshapen) compared to con-
trols (Fig 4B; P< 0.01).
Mechanism of anti-schistosome action of Rubb12-tri and Rubb16-tnl
Adult worms were cultured in the presence of sub-lethal concentrations (5 μM) of Rubb12-
tri or Rubb16-tnl—the two ruthenium compounds deemed to be most effective at killing
adult parasites—for 24 h and then examined for changes in surface and somatic AChE activ-
ity and glucose uptake (given this pathway can be ablated by an organophosphorus AChE
inhibitor). Treated worms showed significantly decreased levels of surface and somatic
AChE activity in the presence of each complex (Fig 5A and 5B) however, consistent with
enzyme inhibition experiments using parasite extracts, AP activity was not significantly
affected (Fig 5C).
The amount of glucose in the media of parasites treated with either complex was signifi-
cantly higher than control worms (Fig 6A), suggestive of impaired glucose uptake in the pres-
ence of ruthenium compounds. Consistent with these results, extracts of treated parasites had
a significantly lower glycogen content compared to controls (Fig 6B). Moreover, scanning elec-
tron micrographs of the tegument of male parasites treated with Rubb12-tri or Rubb16-tnl
showed the dorsal tubercules (a site of glycogen storage [38]) to be withered and flattened
(Fig 6C).
Fig 3. Activity of ruthenium complexes against adult S. mansoni worms. (A) Selective representation of survival of parasites (cultured in
Basch media) after treatment with Ru complexes (50 μM). Data represents the average of duplicate experiments ± SE. (B) Survival of parasites
(cultured in Basch media) after treatment with various concentrations of the most potent ruthenium complexes determined from the screening
experiment. Data represents the average of duplicate experiments ± SE. (C) Alteration in general morphology of adult S. mansoni worms
caused by ruthenium complexes. I: control parasites; II: parasites treated with Rubb12-tri.
https://doi.org/10.1371/journal.pntd.0006134.g003
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Toxicity of Rubb12-tri and Rubb7-tnl
The toxicity of Rubb12-tri and Rubb7-tnl, two of the ruthenium complexes shown to have high
in vitro efficacy against all schistosome stages tested, was assessed against human bile duct cells
and in male BALB/c mice (6–8 weeks) before investigating their in vivo efficacy in a mouse
model of schistosomiasis. PZQ and dichlorvos—a metabolite of the anti-schistosome AChE
inhibitor metrifonate—were included in the study for comparison. When Rubb12-tri and
Rubb7-tnl were used at 5 μM, a concentration where they significantly inhibited surface and
somatic Sm-AChE activity and glucose uptake in adult worms, cell viability was 42% and 73%
for Rubb12-tri and Rubb7-tnl, respectively. The EC50 values of Rubb12-tri and Rubb7-tnl were
calculated as 3.489 ± 0.532 μM and 6.829 ± 0.625 μM, respectively. Dichlorvos was highly toxic
to the cells, killing 100% of the cells even at 0.1 μM (Fig 7). To determine the MTD in mice,
Rubb12-tri or Rubb7-tnl was administered to groups of male BALB/c mice (6–8 weeks). Rubb7-
tnl did not show any toxicity even after five consecutive daily injections (the proposed dosage
frequency of the in vivo drug efficacy study) of 10 mg/kg (mice were adversely affected at doses
of 20 mg/kg) and so the MTD of Rubb7-tnl was considered to be at least 10 mg/kg. The MTD
of Rubb12-tri, using the same dosage frequency, was determined to be 2 mg/kg (mice were
adversely affected at doses of 4 mg/kg). If 100% bioavailability is assumed due to i.v. adminis-
tration, the host bloodstream concentrations of Rubb7-tnl and Rubb12-tri at the MTD can be
approximated at 12 μM and 49 μM, respectively.
In vivo efficacy of Rubb12-tri and Rubb7-tnl
Over two independent trials, a significant reduction in worm burden (42%, P = 0.009) was
seen in mice treated with Rubb12-tri compared to controls whereas a non-significant trend
Fig 4. Inhibition of S. mansoni egg hatching and effect on egg development by ruthenium complexes. (A) Graph representing the
percentage of S. mansoni eggs hatched (motility index) in the presence of various ruthenium complexes (50 μM) as determined by the x-WORM
motility assay. Data represents the average of triplicate experiments ± SE. (B) Triplicate sets of five pairs of adult S. mansoni worms were
cultured in Basch media with or without 5 μM Rubb12-tri for 72 h. The eggs released into the media were counted and those that were
misshapen or immature were scored as “abnormally developed”. Graph shows the difference in percentage of normally developed eggs
between treated and control groups and data represents the average of triplicate experiments ± SE. Differences in egg hatching were measured
by ANOVA and differences in egg development by t test. *P 0.05, **P 0.01, ***P 0.001,****P 0.0001.
https://doi.org/10.1371/journal.pntd.0006134.g004
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towards decreased worm burden was observed in Rubb7-tnl-treated mice (Fig 8A). Surface
AChE activity was decreased in worms collected from mice treated with ruthenium complexes
but only reached significance for Rubb12-tri-treated animals (Fig 8B). Surface SmNPP-5, sur-
face Sm-AP, somatic AChE and glucose uptake activity was not significantly different.
Although there was no decrease in parasite egg burden (as determined by recovery of ova
from the liver), the viability of these eggs from trial 1 was examined and highly significant
(P< 0.0001) reductions in hatching capability (68% and 56%) were observed for the Rubb12-
tri- and Rubb7-tnl-treated mice, respectively (Fig 8C). Egg hatching viability was not deter-
mined for trial 2. Moreover, eggs released from worms recovered from treated mice (trial 2)
were significantly different (P< 0.0001) in terms of their development (immature, misshapen,
eggshell malformation) compared to those from parasites recovered from control mice (Fig
8D and 8E). Morphology of eggs released from worms recovered from mice in trial 1 was not
determined.
Discussion
Control of schistosomiasis, a neglected tropical disease which affects over 200 million peo-
ple, relies on periodic treatment with single drug, PZQ, a strategy that is unsustainable in its
current form [5–8]. As no new anti-schistosome drug (or any anti-parasitic) has been regis-
tered in the last decade [39], the need for additional therapeutic compounds has become
Fig 5. Action of Rubb12-tri and Rubb16-tnl on adult S. mansoni AChE and AP activity. Five pairs of worms were cultured in Basch media
for 24 h in the presence of a sub-lethal dose (5 μM) of Rubb12-tri or Rubb16-tnl and then incubated in AChE assay buffer or AP assay buffer.
PBS extracts were then made from equal amounts of control and treated worms and 30 μg of each extract was used to determine somatic
AChE activity by the Ellman method. (A) surface AChE (B) somatic AChE and (C) surface AP activity of control worms and worms treated with
Rubb12-tri or Rubb16-tnl. For all assays, data are the average of triplicate biological and technical experiments ± SE. Differences were measured
by ANOVA. *P 0.05, **P 0.01, ***P 0.001, ****P 0.0001.
https://doi.org/10.1371/journal.pntd.0006134.g005
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unquestionable and has driven research efforts towards the discovery of alternative anti-
schistosome chemotherapies, including those derived from natural products [40] and metal-
based compounds [41]. Accordingly, this study has described the anti-schistosome efficacy
of a series of mono- and multi-nucleated metal-based compounds (ruthenium complexes)
which exert their action through the inhibition of AChE, an enzyme pivotal to the control of
worm neuromuscular function and implicated in the mediation of host glucose scavenging
[11, 42].
It has been previously shown that mononuclear ruthenium complexes inhibit AChE (E.
electricus) by a non-competitive or mixed mode of inhibition [18]. However, in the present
study, the trinuclear complex (Rubb12-tri) displayed a competitive mode of inhibition in the
kinetic experiments. The mononuclear polypyridylruthenium(II) complexes are thought to
interact with the peripheral anionic site (PAS) of AChE located at the rim of the active-centre
gorge through a combination of electrostatic and hydrophobic interactions [43]. The tri- and
tetra-nuclear complexes showed greater activity compared to mononuclear complexes, pre-
sumably due to the presence of the flexibly-linked multiple metal centres which may provide
more interactions (electrostatic and hydrophobic) with the PAS, or each individual centre may
contribute nonspecific additional points of contact. The activity of the ruthenium complexes
varied in extracts made from different life stages (adult extracts and SEA) and various species
Fig 6. Effect of Rubb12-tri and Rubb16-tnl on adult S. mansoni glucose uptake and storage ability. Worms were cultured in Basch
media for 24 h in the presence of a sub-lethal dose (5 μM) of Rubb12-tri or Rubb16-tnl. Worms were then incubated for 24 h in DMEM
containing 1 mg/ml glucose. PBS extracts were then made from equal amounts of control and treated worms and 30 ug of each extract
was used to determine the glycogen content of the worms using a modified glucose oxidase assay. (A) Amount of glucose in media
collected from control and treated S. mansoni worms. (B) Levels of glycogen in extracts made from control and treated S. mansoni
worms. For all assays, data are the average of triplicate biological and technical experiments ± SE. Differences were measured by
ANOVA. *P 0.05, **P 0.01, ***P 0.001, ****P 0.0001. (C) Scanning electron micrographs of adult male S. mansoni worm
tegument after incubation with 5 μM Rubb12–tri; (I) intact tubercles of control worms; (II) withered tubercules of treated worms.
https://doi.org/10.1371/journal.pntd.0006134.g006
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of the parasite which is most likely due to differences in enzyme orthologues and the existence
of multiple isoforms of AChE which are present in different life stages and species [42].
Encouraged by the activity of ruthenium complexes against parasite extracts, we tested the
compounds against all three intra-mammalian stages of the parasite in vitro and found similar
trends in anti-parasite activity as was seen for extracts; i.e., the tri- and tetra-nucleated com-
plexes were more effective against each stage of the parasite than the mono- and di-nuclear
compounds. Three of the most effective compounds in terms of their combined activity
against S. mansoni extracts and all intra-mammalian stages were Rubb7-tnl, Rubb12-tri and
Rubb16-tnl. Further, Rubb12-tri was also the most effective at inhibiting AChE activity in S.
haematobium extracts; availability of material prevented us from doing any experiments on
live parasites or eggs but we believe that that the similar trends observed between S. mansoni
anti-parasitic activity and extract activity hold true for S. haematobium and ruthenium com-
plexes such as Rubb12-tri would display potent anti-schistosome activity against this species.
Further, S. haematobium has higher levels of tegumental AChE than S. mansoni, which makes
the parasite more sensitive to AChE inhibitors [44] and might render this species more vulner-
able to ruthenium drugs.
Any differences observed between the AChE-inhibitory ability and anti-schistosome effect
of ruthenium complexes could be due to the target of these drugs not solely being AChE.
While we showed that ruthenium complexes did not have any inhibitory effects on the major
tegumental enzymes SmNPP-5 and AP, these drugs have been documented to act as dual
inhibitors of telomerase and topoisomerase [45], thioredoxin reductase [46] and protein and
lipid kinases [43]. There are numerous reports in the literature documenting the development
of drug resistance in parasites due to mutation (for example, benzamidazole resistance in
nematodes due to single nucleotide polymorphisms in β-tubulin [47] and mutation of a
Fig 7. Cytotoxicity of ruthenium complexes. Toxicity against human bile duct cells (H69) after 72 h incubation with
Rubb12-tri or Rubb7-tnl, praziquantel and dichlorvos—an organophosphorus AChE inhibitor—as determined by the MTT
cell viability assay. Data are the average of six replicate experiments ± SE.
https://doi.org/10.1371/journal.pntd.0006134.g007
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schistosome sulfotransferase resulting in resistance to oxamniquine [48], and so the use of a
drug that is directed against multiple molecular targets may decrease the chance of resistance
evolving.
Visually, the effects of the compounds were most pronounced against adult worms, which
became immobile and coiled when incubated with ruthenium complexes, possibly due to
paralysis induced by AChE inhibition and cholinergic accumulation, effects similarly seen in
schistosomes treated with other inhibitors of AChE [49–51]. This observation should be
treated with caution, however, as other drugs, such as PZQ (which is not a cholinesterase
inhibitor), induce the same morphological changes. Additional evidence of the mechanistic
effects of ruthenium complexes on schistosomes manifested in the reduced glucose uptake
observed in drug-treated worms, potentially a consequence of inhibiting the tegumental
AChE-mediated regulation of host glucose scavenging, a pathway unique to schistosomes [11].
Further confirmation of this inhibition was evidenced by significantly depleted glycogen stores
(quantified in parasite extracts and observed by the withering of male tubercules—a site of gly-
cogen storage [38]) in these parasites, an effect seen in worms recovered from mice treated
Fig 8. In vivo effect of Rubb12-tri and Rubb7-tnl on S. mansoni-infected mice. (A) Effect of Rubb12-tri and Rubb7-tnl on adult worm burden. Symbols
represent data from individual mice and are the combination of two independent trials (trial 1 PBS control—n = 8 mice, trial 1 Rubb12-tri-treated—n = 8 mice,
trial 1 Rubb7-tnl-treated—n = 6 mice, trial 2 PBS control—n = 7 mice, trial 2 Rubb12-tri-treated—n = 7 mice, trial 2 Rubb7-tnl-treated—n = 8 mice). (B) Surface
AChE activity of worms recovered from control and treated mice. Data are the average of triplicate technical assays ± SE on extracts made from worms (five
pairs) pooled from each group of each of the two trials. (C) Hatching viability of eggs obtained from the pooled livers of control and treated mice from trial 1
(PBS control—n = 8, Rubb12-tri-treated—n = 8, Rubb7-tnl-treated—n = 6). Data are the average of ten replicate counts ± SE of hatched miracidia. (D) Eggs
were harvested from triplicate sets of worms (five pairs) from a pool of each group of trial 2 (PBS control—n = 7 mice, Rubb12-tri-treated—n = 7 mice, Rubb7-
tnl-treated—n = 8 mice) after culturing the parasites for 24 h in Basch media and the percentage of mature, morphologically “normal” eggs released from
worms recovered from control and treated mice was assessed. Data are the average counts ± SE of eggs released from triplicate sets (five pairs) of worms
from trial 2. Differences were measured by ANOVA. *P 0.05, **P 0.01, ***P 0.001, ****P 0.0001. (E) Auto-fluorescence images (20×) of eggs
released from worms recovered from (I and II) control and (III and IV) treated mice.
https://doi.org/10.1371/journal.pntd.0006134.g008
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with carbamate-based AChE inhibitors [38]. In another example of tegument-mediated glu-
cose regulation, previous work by You and colleagues [52] has shown that inhibition of schis-
tosome insulin receptor activity significantly decreased glucose uptake by the parasite. It
would be interesting to explore any relationship that existed between these two regulatory
mechanisms, a possibility given the alternative is to imagine the evolution of two mechanisti-
cally distinct pathways of glucose regulation. Additionally, a combination chemotherapeutic
strategy could be developed using drugs which target different aspects of schistosome glucose
uptake.
Two of the ruthenium complexes which we considered most effective in vitro (Rubb12-tri
and Rubb7-tnl) were tested for cytotoxicity before assessment of their in vivo efficacy in a
mouse model of schistosomiasis. Rubb16-tnl, even though effective in vitro, was not included
in the cytotoxicity assay or the in vivo study as earlier work by us has shown that ruthenium
complexes with longer chain lengths are more toxic to eukaryotic cells [24]. Both ruthenium
complexes tested, Rubb7-tnl and Rubb12-tri, exhibited lower cytotoxicity against eukaryotic
cells (H69) compared to dichlorvos, an organophosphorus AChE inhibitor and previously
licensed, but now withdrawn, anti-schistosome drug. Further, studies comparing AChE from
schistosomes and higher eukaryotes [53, 54] reveal differences in functionally important
amino acid residues (human AChE shares 33–36% primary sequence homology across all
schistosome AChEs) with the active site serine conserved across species. It was previously
shown that dichlorvos covalently binds to the active site serine and reduces the AChE activity
in eukaryotes (e.g. in rat forebrain, erythrocytes and plasma) [55, 56]. By contrast, it was con-
sidered that the ruthenium complexes may be relatively less toxic to mice than dichlorvos due
to the differential binding to AChE. The results of the MTD study, where both the ruthenium
complexes were well tolerated by mice, supported this argument.
Rubb12-tri and Rubb7-tnl both showed promising in vivo efficacy at doses which were equiv-
alent to lethal in vitro concentrations yet well tolerated in mice, with Rubb12-tri-treated mice
showing a significant reduction in worm burden and recovered worms displaying a small but
significant decrease in tegumental AChE activity, providing evidence that the anti-schistosome
effect may be partially due to AChE inhibition. Studies by us on di-nuclear ruthenium com-
plexes have shown the compounds to have a short serum half-life [57], and the different in vivo
efficacies of each complex in this study may be attributed to differences in the pharmacoki-
netic/pharmacodynamic (PK/PD) properties of Rubb12-tri and Rubb7-tnl. Although these
experiments have yet to be performed, the differences exhibited between these two compounds
in the cytotoxicity assay and tolerability study suggests that their PK/PD are not the same.
Despite no significant reduction in egg burden in both trials, ova recovered from both Rubb12-
tri- and Rubb7-tnl-treated mice had significantly reduced hatching ability and were morpho-
logically abnormal compared to controls, in agreement with in vitro data. That there was no
decrease in egg burden in light of a reduced worm load in either treated group was surprising,
but this did result in an increase in the number of eggs per female in these groups, compared to
controls. To explain these observations, we postulate that treatment with ruthenium drugs may
stimulate schistosome reproductive tract motility (AChE inhibitors have been shown to stimu-
late gastrointestinal motility in various organisms [58, 59]), resulting in premature release of
under-developed eggs, and have a direct effect on egg formation, resulting in abnormally devel-
oped eggs (studies in ticks have shown that treatment with AChE inhibitors effect ova develop-
ment [60, 61]). Another possible factor contributing to abnormal egg development is that the
worms are under-nourished due an impaired glucose uptake ability (albeit an effect we could
only measure in vitro) resulting from ruthenium drug treatment and unable to meet the ener-
getically demanding task of producing normally developed ova. There is considerable interest
in the use of agents that show ovicidal activity or affect oviposition to control schistosomiasis
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due to their ability to block transmission of the disease. In this regard, ruthenium complexes
offer a potential advantage over PZQ in that it is only effective against mature worms and so
cannot be used to interrupt disease transmission, as evidenced by high rates of re-infection in
PZQ-treated endemic populations [62].
To our knowledge, this is the first report detailing the anti-parasitic activity of ruthenium
complexes and this work has identified some lead anti-schistosome compounds. The modular
nature of ruthenium complexes makes it possible to synthesize these compounds to target spe-
cific enzymes, so future work will involve tailoring Ru complexes to increase their selectivity
and potency. Finally, these complexes could be administered in combination with PZQ, over-
coming the limitations of current monotherapy and augmenting existing schistosomiasis con-
trol initiatives.
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